Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
GE HealthCare drives innovation in theranostics with latest technological advances
GE HealthCare is helping advance clinical and operational excellence in theranostics and…
OptiMIM and Vasantha Tool Crafts Pvt.Ltd. Announce Strategic Joint Venture “OptiMIM Global” to Advance Metal Injection Molding Innovation and Global Reach
PORTLAND, Ore. and HYDERABAD, India, April 8, 2025 /PRNewswire/ -- OptiMIM, a Form…
